DEF: Glucotrack Sets August 18, 2026 Annual Meeting

Glucotrack, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for August 18, 2026, to address key proposals including director elections, executive compensation, auditor ratification, a reverse stock split, and a warrant inducement.

Summary

• Glucotrack, Inc. has scheduled its 2026 Annual Meeting of Stockholders for August 18, 2026, to be held virtually.
• Key proposals include the election of six directors, an advisory vote on 2025 executive compensation (Say-on-Pay), ratification of CBIZ CPAs P.C. as independent auditors for 2026, approval of one or more reverse stock splits up to a 1-for-30 ratio, and approval of a warrant inducement transaction to comply with Nasdaq Listing Rule 5635(d).
• The record date for determining stockholders entitled to vote is July 17, 2026, with 7,719,121 shares of Common Stock outstanding on that date.
• The meeting will be conducted virtually via webcast at www.virtualshareholdermeeting.com/GCTK2026.
• The company urges stockholders to read the proxy statement carefully and vote their shares in advance.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it addresses routine annual meeting matters but also proposes a reverse stock split with inherent risks and a warrant inducement that could lead to significant dilution.

Positives

• The company is holding its annual meeting to allow stockholders to vote on important corporate matters.
• The proposed reverse stock split aims to maintain compliance with Nasdaq listing requirements and potentially improve marketability and liquidity.
• The warrant inducement proposal, if approved, could provide flexibility to incentivize warrant holders for repricing and exercise, potentially generating proceeds for the company.
• The company has a robust board structure with independent directors and established committees (Audit, Compensation, Nominating and Corporate Governance).

Negatives

• The company is proposing a reverse stock split, which carries risks of not increasing the stock price proportionally or leading to further price declines.
• The warrant inducement proposal could lead to significant dilution for existing stockholders.
• There are multiple instances of late filings for Section 16(a) reports by directors and executive officers, indicating potential compliance issues.
• The company has experienced net losses in recent fiscal years (2023-2025), with losses increasing from 2023 to 2025.

Risks

• The proposed reverse stock split may not achieve the desired effect of increasing the stock price or maintaining Nasdaq compliance, and could lead to a greater percentage decline in stock price if it falls.
• A reverse stock split may decrease the liquidity of the company's common stock.
• The warrant inducement transaction could result in significant dilution to existing stockholders, impacting their percentage ownership and potentially causing market price declines.
• Failure to obtain stockholder approval for the warrant inducement could result in the company forgoing proceeds from warrant exercises, potentially impacting its ability to fund operations and working capital needs.
• The company faces cybersecurity risks and other risks detailed in its Form 10-K.

Future Outlook

The company is seeking approval for a reverse stock split to maintain Nasdaq listing and a warrant inducement to potentially raise capital and incentivize warrant holders. The effectiveness of these actions on future stock performance and liquidity is uncertain.

Management Comments

• The Board believes that a reverse stock split may be necessary to maintain our listing on The Nasdaq Capital Market and compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule).
• The Board believes that the independent directors work well together in the current Board structure.
• The Company urges you to read this material carefully and vote your shares.
• The Company believes that its Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and any applicable listing standards.
• We believe these provisions in our Certificate of Incorporation are necessary to attract and retain qualified persons as directors and officers.

Industry Context

StockSavvy.ai notes that Glucotrack's proposed reverse stock split is a common strategy for companies facing potential delisting due to low stock prices, aiming to meet exchange requirements and attract institutional investors. The warrant inducement proposal is also typical for companies seeking to restructure debt or equity while complying with exchange rules.

Comparison to Industry Standards

• Companies in the biotechnology and medical device sectors often face scrutiny regarding stock price and Nasdaq listing requirements. Reverse stock splits are a frequent tool used to address bid price deficiencies, though their long-term effectiveness varies.
• The proposed warrant inducement, involving repricing and issuance of new warrants, is a mechanism sometimes employed to renegotiate terms with warrant holders, particularly when seeking to avoid dilution or secure necessary capital, though it carries inherent dilution risks for existing shareholders.

Management Changes

Corporate Governance

Related Party Transactions

• On October 7, 2022, the Company entered into an Intellectual Property Purchase Agreement with Paul Goode (CEO) for the sale of intellectual property related to a continuous glucose sensor for $1 and the potential issuance of up to 167 shares of Common Stock, with a true-up provision to ensure the issuance represents 1.5% of outstanding Common Stock.
• In April 2024, the Company issued 3,969 shares of Common Stock at $126.0 per share in a private placement, which included participation from certain executive management, Board members, and existing shareholders.
• In June 2024, the Company entered into note and warrant purchase agreements with certain officers, directors, and existing investors for $100,000 in unsecured promissory notes and warrants to purchase up to 250 shares of Common Stock.
• In July 2024, the Company entered into convertible promissory notes with aggregate principal of $360,000 with certain officers and directors, with interest at 8% per annum, convertible upon a Qualified Financing or due on the 12-month anniversary.
• In July 2024, the Company entered into a secured convertible promissory note for $4,000,000 with an existing investor controlled by a director, with 8% interest, secured by all company assets, and convertible upon stockholder approval or due on the 12-month anniversary.
• In November 2024, the investor controlled by a director converted approximately $4,093,112 of debt into Common Stock and Common Warrants.
• In November 2024, three outstanding July 18 Notes with an aggregate principal and accrued interest of $304,494 were converted into Common Stock and warrants.
• On April 14, 2025, Dr. Victoria Carr-Brendel, a director nominee, through her consulting company, entered into a one-year contracting agreement to assist with business development, paid $3,000 per month.

Stakeholder Impact

• Shareholders: Potential dilution from warrant inducement, potential benefits from reverse stock split if successful in maintaining Nasdaq listing and improving liquidity. Vote on director elections and executive compensation.
• Management: Subject to advisory vote on executive compensation. Erik Emerson appointed CEO, Paul Goode transitions to CTO.
• Creditors: Not directly impacted by proposals, but company's financial health is a consideration.
• Employees: Indirectly impacted by company's financial health and stock performance; equity awards are subject to plans and policies.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on August 18, 2026.
• If approved, management will determine whether to implement the reverse stock split(s) and the specific ratio(s) up to the 1-for-30 maximum, to be effected on or prior to the one-year anniversary of the Annual Meeting.
• If approved, the company may, within six months following stockholder approval, effect one Warrant Inducement transaction.
• Final voting results will be published in a Form 8-K filing with the SEC within four business days after the Annual Meeting.

Key Dates

Recommendation

The filing outlines standard annual meeting proposals, including director elections and executive compensation. However, the proposed reverse stock split carries significant risks of not improving stock price or liquidity, and the warrant inducement could lead to substantial dilution. While these actions aim to address Nasdaq compliance and potential capital needs, the uncertainty and risks involved suggest a 'hold' recommendation pending further clarity on their execution and impact.

Keywords

Glucotrack, Proxy Statement, Annual Meeting, DEF 14A, Reverse Stock Split, Warrant Inducement, Executive Compensation, Director Election